Mabion (FRA:272) FFO


FRA:272 Mabion SA FRA:272
22 GF Score
Price €1.73
GF Value €0.48
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion FFO?

FFO (Funds from operations) only applies to REITs.

FRA:272
22GF Score
Mabion SA FRA:272
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (FRA:272) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of €1.73 is trading 260.8% above its estimated GF Value™ of €0.48. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for FRA:272:

  • FFO:
  • GF Value™: €0.48 vs. price of €1.73 (260.8% above fair value)
  • GF Score™: 22/100 with 4 warning signs

No single metric tells the full story. See the FRA:272 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mabion Business Description

Other Exchanges MAB:Poland
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
22GF Score

Get the complete analysis for FRA:272

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price
€0.48
GF Value